|

Decitabine and Cedazuridine Clinical Trials

9 actively recruiting trials across 5 locations

▼ -1 trial since July 2026

Also known as: ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727 +5 more

Pipeline

Phase 1: 4Phase 2: 3Phase 1/2: 2

Top Sponsors

  • National Cancer Institute (NCI)5
  • M.D. Anderson Cancer Center3
  • University of Washington1

Indications

  • Cancer9
  • Acute Myeloid Leukemia6
  • Refractory Acute Myeloid Leukemia4
  • Recurrent Acute Myeloid Leukemia4
  • Myelodysplastic Syndrome3

Birmingham, Alabama3 trials

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Children's Hospital of Alabama

Phase 1
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

University of Alabama at Birmingham Cancer Center

Phase 1

Houston, Texas3 trials

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

M D Anderson Cancer Center

Phase 1
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Tucson, Arizona1 trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Banner University Medical Center - Tucson

Phase 2

New Haven, Connecticut1 trial

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Yale University

Phase 1

Seattle, Washington1 trial

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.